Picking any small molecule GLP1 is not likely to be as effective.
Agreed, given your use of the word, “any.” However, in this thread I’m talking about a hypothetical best-in-class small-molecule obesity drug—maybe but not necessarily a GLP-1. Right now, we don’t know if such a drug will emerge, but I think it’s pretty likely that it will.
Market Data 
Markets 
AI
